Univec announces completion of R&D for Nicotine Replacement Patch

OWINGS MILLS, Md.--()--Univec, Inc. (OTC: UNVC) a specialty pharmaceutical company, announces it has completed the R&D for its Nicotine Replacement Patch. Univec anticipates product production by the end of next quarter. Univec's Transdermal Delivery system enhances bioavailability, minimizes pharmaco-kinetic peaks, improves tolerability and dosing, increases patient compliance, and continuous delivery.

David L. Dalton, President and CEO of Univec stated, “We are delighted to continue making progress in our new business model. Over the last decade deaths due to smoking have increased drastically. Over 45 million people smoke worldwide, 70% of the people would like to quit. 440,000 deaths each year are caused by smoking. City, States, Federal agencies recognize the need to stop this and are providing financial assistance and Quitline programs and products. We feel that our products will be one of the solutions.”

About Univec

Univec, Inc., a minority business enterprise (MBE), is a Specialty Pharmaceutical Company that manufactures and distributes high cost Specialty Pharmaceuticals. Specialty Pharmaceuticals are high cost products that are not usually dispensed in retail pharmacies but require special handling and a complex pharmaceutical regime. The company is focused on diseases such as Sickle Cell Anemia, Cancer, HIV/Aids, Hepatitis C., Multiple Sclerosis, Hemophilia and Smoking and Drug addiction.

PPSI (PHYSICIAN AND PHARMACEUTICAL SERVICES, INC.), a subsidiary of Univec, promotes and pays for pharmaceutical products though its network of pharmacies. PPSI eliminates the need for the pharmaceutical companies to distribute actual drug samples to physicians reducing potential liability for the physician while maintaining clinical oversight and drug interaction checks for the patient. The company through its “StarterScript” allows in lieu of a physician sample, a voucher or a co-payment card to be provided to the patient for a trial supply of medication redeemed at any of the nearly 55,000 retail pharmacies utilizing the PPSI real-time processing system.

Forward Looking Statements

This document may contain forward-looking statements based on current expectations that could be affected by the risks and uncertainties involved in Univec’s business. These risks and uncertainties include, but are not limited to, the risks described from time to time in Univec’s reports to the General Public and reporting agencies. Subsequent written or oral statements attributable to Univec or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements in this document and those in Univec’s reports filed.

Contacts

Univec, Inc.
David Dalton, President
443-253-0194
univec@univecinc.com

Release Summary

Univec Moves Forward on Pharmaceutical Transdermal Delivery

Contacts

Univec, Inc.
David Dalton, President
443-253-0194
univec@univecinc.com